Online first
Short communication
Published online: 2024-11-14
Time efficiency and safety of antazoline in the rapid cardioversion of recent onset atrial fibrillation during supraventricular arrhythmias ablation
Abstract
Not available
References
- Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021; 42(5): 373–498.
- Srzednicki M, Sadowski Z, Kulikowski A. Evaluation of the anti‐arrhythmia effectiveness of Phenazolinum Polfa in paroxysmal atrial fibrillation. Pol Tyg Lek. 1990; 45: 924–927.
- Balsam P, Koźluk E, Peller M, et al. Antazoline for termination of atrial fibrillation during the procedure of pulmonary veins isolation. Adv Med Sci. 2015; 60(2): 231–235.
- Maciag A, Farkowski M, Chwyczko T, et al. Efficacy and safety of antazoline in the rapid cardioversion of paroxysmal atrial fibrillation (the AnPAF Study). EP Europace. 2016; 19(10): 1637–1642.
- Karwowski J, Wrzosek K, Mączyńska-Mazuruk R, et al. Efficacy and safety of antazoline vs propafenone for conversion of paroxysmal atrial fibrillation to sinus rhythm: a randomized, double-blind study (AnProAF). Pol Arch Intern Med. 2024; 134(4): 16657.
- Njoku A, Kannabhiran M, Arora R, et al. Left atrial volume predicts atrial fibrillation recurrence after radiofrequency ablation: A meta-analysis. Europace. 2018; 20(1): 33–42.
- Krummen DE, Swarup V, Narayan SM. The role of rotors in atrial fibrillation. J Thorac Dis. 2015; 7(2): 142–151.
- Wybraniec MT, Maciąg A, Miśkowiec D, et al. Efficacy and safety of antazoline for cardioversion of atrial fibrillation: propensity score matching analysis of a multicenter registry (CANT II Study). Pol Arch Intern Med. 2022; 132(6): 16234.
- Bińkowski BJ, Makowski M, Kubiński P, et al. Effect of antazoline on electrophysiological properties of atrial muscle and conduction system of the heart. Cardiovasc Drugs Ther. 2018; 32(2): 169–173.
- Wybraniec MT, Maciąg A, Miśkowiec D, et al. Antiarrhythmic drugs for pharmacological cardioversion of atrial fibrillation and sex differences: Insights from the CANT II Study. Kardiol Pol. 2023; 81(11): 1089–1095.
